✦ LIBER ✦

Using low molecular weight heparin in special patient populations

✍ Scribed by Wendy Lim

Publisher: Springer US
Year: 2009
Tongue: English
Weight: 171 KB
Volume: 29
Category: Article
ISSN: 0929-5305
DOI: 10.1007/s11239-009-0418-z

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pharmacology and special clinical applic

Pharmacology and special clinical applications of low-molecular-weight heparins

✍ Priv.-Doz. Dr. med J. Harenberg; D. L. Heene 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 825 KB

A low molecular weight heparin in hemodi

A low molecular weight heparin in hemodialysis

✍ Maurin, N. ;Kierdorf, H. 📂 Article 📅 1988 🏛 Springer-Verlag 🌐 English ⚖ 536 KB

Thromboprophylaxis with low-molecular-we

Thromboprophylaxis with low-molecular-weight heparin in medical patients with cancer

✍ Gary H. Lyman 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 312 KB

Low molecular weight heparin stimulates

Low molecular weight heparin stimulates megakaryocytopoiesis in bone-marrow transplantation patients

✍ Or, Reuven; Elad, Sharon; Shpilberg, Ofer; Eldor, Amiram 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 205 KB 👁 2 views

The use of low molecular weight heparin (LMWH) as prophylaxis for veno-occlusive disease of the liver has been studied in patients undergoing bone marrow transplantation (BMT). The present study analyzes the effect of LMWH on the time course of platelet recovery after BMT. Significantly accelerated

Low molecular weight heparin for deep ve

Low molecular weight heparin for deep vein thrombosis in glioma patients

✍ Friederike Schmidt; Christoph Faul; Johannes Dichgans; Michael Weller 📂 Article 📅 2002 🏛 Springer 🌐 English ⚖ 154 KB

Unfractionated- versus low-molecular-wei

Unfractionated- versus low-molecular-weight-heparin-associated HIT in hospitalized medical patients

✍ Gilles L. Fraser; Richard R. Riker 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 47 KB

I n the pharmacoeconomic evaluation of enoxaparin versus un- fractionated heparin (UFH) for the prevention of venous thrombosis in medical patients, Leykum et al. 1 concluded that lowmolecular-weight heparin (LMWH) offered greater cost utility. This important benefit was based on a single advantage